Calliditas Therapeutics Ab (CALT) has released an update.
Calliditas Therapeutics AB reports positive outcomes from their Phase 2 trial for setanaxib, a treatment for head and neck cancer, showing significant improvements in patient survival rates and progression-free survival. The trial results, which also noted increased tumor immunological activity, suggest setanaxib’s potential as an effective therapy for this challenging condition. The company is preparing for further clinical studies and will share more detailed findings at an upcoming R&D day in Stockholm.
For further insights into CALT stock, check out TipRanks’ Stock Analysis page.
